Xolair 150 MG/ML syringeml
Ended Awarded
- Contract number
- SPE2DB25FDRCN
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $18,569
Award facts
- Contract value 100% obligated
- $18,568.80 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
This delivery order, issued on September 25, 2025, awards DMS Pharmaceutical Group Inc. a firm fixed-price contract valued at $18,568.80 for the supply of Xolair 150 mg/ml syringes to support Department of Defense healthcare operations. The award represents a delivery order issued under DMS Pharmaceutical Group's larger Indefinite Delivery Contract with the Defense Logistics Agency (DLA), a $500 million SPE2DB program contract valid through November 2026. The contract carries no set-aside designation. Performance will be completed by October 17, 2025, with delivery to the company's facility in Park Ridge, Illinois.
DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler established in 2001, serves as a critical supplier within the federal pharmaceutical supply chain. The contractor leverages its DLA master contract to distribute branded and generic prescription drugs, biologics, and medical consumables to military health facilities nationwide. Xolair (omalizumab), a monoclonal antibody used in treating moderate-to-severe asthma and other allergic conditions, represents the specialized pharmaceutical products the company regularly supplies to Department of Defense healthcare systems. This delivery order exemplifies the DLA's routine procurement of essential medications through established indefinite delivery vehicles to ensure consistent pharmaceutical availability across military medical facilities.
Quick answers
Who was awarded contract SPE2DB25FDRCN?
SPE2DB25FDRCN was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on September 25, 2025.
How much is contract SPE2DB25FDRCN worth?
The government has obligated $18,569 on SPE2DB25FDRCN.
Is contract SPE2DB25FDRCN an order under another contract?
Yes. SPE2DB25FDRCN is a delivery order under SPE2DB24D9238, an indefinite delivery contract.
Was contract SPE2DB25FDRCN competed?
The extent of competition for SPE2DB25FDRCN was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award